Consistent with its potential as a marker of breast cancer aggressiveness, JMJD6 was expressed at highest levels in ER-, basal, claudin-low, HER2-enriched, and Luminal B tumor subtypes, which are known to be clinically associated with poor patient outcomes. This evidence concerns the gene ERBB2 and neoplasm.